Literature DB >> 19764786

Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.

Markus Fridén1, Susanne Winiwarter, Gunilla Jerndal, Ola Bengtsson, Hong Wan, Ulf Bredberg, Margareta Hammarlund-Udenaes, Madeleine Antonsson.   

Abstract

New experimental methodologies were applied to measure the unbound brain-to-plasma concentration ratio (K(p,uu,brain)) and the unbound CSF-to-plasma concentration ratio (K(p,uu,CSF)) in rats for 43 structurally diverse drugs. The relationship between chemical structure and K(p,uu,brain) was dominated by hydrogen bonding. Contrary to popular understanding based on the total brain-to-plasma concentration ratio (logBB), lipophilicity was not a determinant of unbound brain exposure. Although changing the number of hydrogen bond acceptors is a useful design strategy for optimizing K(p,uu,brain), future improvement of in silico prediction models is dependent on the accommodation of active drug transport. The structure-brain exposure relationships found in the rat also hold for humans, since the rank order of the drugs was similar for human and rat K(p,uu,CSF). This cross-species comparison was supported by K(p,uu,CSF) being within 3-fold of K(p,uu,brain) in the rat for 33 of 39 drugs. It was, however, also observed that K(p,uu,CSF) overpredicts K(p,uu,brain) for highly effluxed drugs, indicating lower efflux capacity of the blood-cerebrospinal fluid barrier compared to the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19764786     DOI: 10.1021/jm901036q

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  56 in total

1.  P2X receptor antagonists for pain management: examination of binding and physicochemical properties.

Authors:  Rebecca J Gum; Brian Wakefield; Michael F Jarvis
Journal:  Purinergic Signal       Date:  2011-11-16       Impact factor: 3.765

Review 2.  Improving the prediction of the brain disposition for orally administered drugs using BDDCS.

Authors:  Fabio Broccatelli; Caroline A Larregieu; Gabriele Cruciani; Tudor I Oprea; Leslie Z Benet
Journal:  Adv Drug Deliv Rev       Date:  2011-12-21       Impact factor: 15.470

Review 3.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

4.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

Review 5.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

6.  Computational prediction of CNS drug exposure based on a novel in vivo dataset.

Authors:  Christel A S Bergström; Susan A Charman; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2012-06-29       Impact factor: 4.200

Review 7.  Non-synaptic receptors and transporters involved in brain functions and targets of drug treatment.

Authors:  E S Vizi; A Fekete; R Karoly; A Mike
Journal:  Br J Pharmacol       Date:  2010-02-05       Impact factor: 8.739

8.  Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.

Authors:  Irena Loryan; Vikash Sinha; Claire Mackie; Achiel Van Peer; Wilhelmus Drinkenburg; An Vermeulen; Denise Morrison; Mario Monshouwer; Donald Heald; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

Review 9.  Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.

Authors:  Nithya Srinivas; Kaitlyn Maffuid; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

10.  Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling.

Authors:  Qianwen Wang; Yufeng Zhang; Chun-Ho Wong; H Y Edwin Chan; Zhong Zuo
Journal:  AAPS J       Date:  2017-12-27       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.